naratriptan has been researched along with Recrudescence in 8 studies
naratriptan: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rizatriptan was more effective than naratriptan." | 2.69 | Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. ( Allen, C; Bomhof, M; Legg, N; Patel, K; Paz, J; Vandormael, K, 1999) |
| ") In a subset of patients experiencing headache relief after 2 attacks, headache recurrence 4 to 24 hours after initial dosing was reported by 55 naratriptan- and 77 sumatriptan-treated patients (41% and 57%, respectively; P = 0." | 2.69 | Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. ( Becker, W; Boswell, D; Crisp, A; Göbel, H; Hauge, T; Mihout, B; Niewold, J; Tørring, J; Winter, P, 2000) |
| "Naratriptan was also more effective than placebo in reducing clinical disability and the incidences of nausea, photophobia, and phonophobia." | 2.68 | Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. ( Asgharnejad, M; Laurenza, A; Mathew, NT; Peykamian, M, 1997) |
| "Two new intranasal migraine medications, sumatriptan and dihydroergotamine mesylate, may offer specific advantages for patients who are seeking alternatives to various oral or parenteral migraine abortive therapies." | 2.41 | Newer intranasal migraine medications. ( Logemann, CD; Rankin, LM, 2000) |
| "Eletriptan 40 mg also was found to have the lowest total triptan cost to successfully treat 100 patients." | 1.33 | Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. ( Healey, PJ; Mullins, CD; Perfetto, EM; Subedi, PR; Weis, KA, 2005) |
| "Treating less severe migraine attacks, treating earlier within an attack, and obtaining complete relief post dose may enhance the low incidence of headache recurrence and achieve longer times to recurrence with naratriptan, 2." | 1.31 | Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. ( O'Quinn, S; Pait, D; Sheftell, F; Watson, C; Winter, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mullins, CD | 1 |
| Weis, KA | 1 |
| Perfetto, EM | 1 |
| Subedi, PR | 1 |
| Healey, PJ | 1 |
| Mathew, NT | 1 |
| Asgharnejad, M | 1 |
| Peykamian, M | 1 |
| Laurenza, A | 1 |
| Deleu, D | 1 |
| Hanssens, Y | 1 |
| Bomhof, M | 1 |
| Paz, J | 1 |
| Legg, N | 1 |
| Allen, C | 1 |
| Vandormael, K | 1 |
| Patel, K | 1 |
| Logemann, CD | 1 |
| Rankin, LM | 1 |
| Sheftell, F | 1 |
| O'Quinn, S | 1 |
| Watson, C | 1 |
| Pait, D | 1 |
| Winter, P | 2 |
| Göbel, H | 1 |
| Boswell, D | 1 |
| Crisp, A | 1 |
| Becker, W | 1 |
| Hauge, T | 1 |
| Mihout, B | 1 |
| Niewold, J | 1 |
| Tørring, J | 1 |
| Potrebic, S | 1 |
| Raskin, NH | 1 |
3 reviews available for naratriptan and Recrudescence
| Article | Year |
|---|---|
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
Topics: Acute Disease; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Vasospasm; Drug Des | 1999 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic | 2000 |
New abortive agents for the treatment of migraine.
Topics: Clinical Trials as Topic; Female; Humans; Indoles; Male; Migraine Disorders; Oxazolidinones; Piperid | 2001 |
3 trials available for naratriptan and Recrudescence
| Article | Year |
|---|---|
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Gastrointestinal Diseases; | 1997 |
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Male; Middle | 1999 |
Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Indoles; Middle Ag | 2000 |
2 other studies available for naratriptan and Recrudescence
| Article | Year |
|---|---|
Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
Topics: Algorithms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Humans; Mana | 2005 |
Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
Topics: Acute Disease; Adult; Aged; Female; Humans; Indoles; Male; Middle Aged; Migraine Disorders; Piperidi | 2000 |